Finch Therapeutics Presents Positive Data from PRISM3 Clinical Trial of CP101 for Recurrent C. difficile at American College of Gastroenterology Annual Scientific Meeting
Finch Therapeutics to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit
Finch Therapeutics Appoints Samuel Allen Hamood to its Board of Directors
Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer
Finch Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Finch Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
Finch Therapeutics Announces Takeda to Accelerate Leadership Role in FIN-524 Ulcerative Colitis Development Program
Finch Therapeutics Added to Russell 2000 and Russell 3000 Indexes
Finch Therapeutics to Present at Upcoming Virtual Investor Conferences
Finch Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates
